Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Cancer-Blood Cancer

Request The Product List ofBlood Cancer Blood Cancer

Blood cancers affect the production and function of your blood cells. Most of these cancers start in your bone marrow where blood is produced. Stem cells in your bone marrow mature and develop into three types of blood cells: red blood cells, white blood cells, or platelets. In most blood cancers, the normal blood cell development process is interrupted by uncontrolled growth of an abnormal type of blood cell. These abnormal blood cells, or cancerous cells, prevent your blood from performing many of its functions, like fighting off infections or preventing serious bleeding.

 There are three main types of blood cancers:

1.Leukemia, a type of cancer found in your blood and bone marrow, is caused by the rapid production of abnormal white blood cells. The high number of abnormal white blood cells are not able to fight infection, and they impair the ability of the bone marrow to produce red blood cells and platelets.

2.Lymphoma is a type of blood cancer that affects the lymphatic system, which removes excess fluids from your body and produces immune cells. Lymphocytes are a type of white blood cell that fight infection. Abnormal lymphocytes become lymphoma cells, which multiply and collect in your lymph nodes and other tissues. Over time, these cancerous cells impair your immune system.

3.Myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that produce disease- and infection-fighting antibodies in your body. Myeloma cells prevent the normal production of antibodies, leaving your body's immune system weakened and susceptible to infection. 

Cat. No. Product Name CAS No. Information
H9590

Revumenib

 		2169919-21-3

Revumenib(SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM; SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
H9556

Enitociclib

 		1610408-97-3

Enitociclib is a potent and highly selective PTEF/CDK9 inhibitor. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins; This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation.
H9525

Pirtobrutinib

 		2101700-15-4

Pirtobrutinib (LOXO-305) is a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations; Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
H9489

Mezigdomide

 		2259648-80-9

Mezigdomide(CC-92480)is a cereblon E3 ubiquitin ligase modulating drug (CELMoD), acts as a molecular glue. CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity.
H9487

Lisaftoclax

 		2180923-05-9

Lisaftoclax is a novel, dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, Bcl-2/Bcl-xl inhibitor 1 exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively;First-in-human study of Lisaftoclax (APG-2575), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
H9481

Inobrodib

 		2222941-37-7

Inobrodib(CCS-1477) is an orally, potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro.
H9467

Flumatinib

 		895519-90-1

Flumatinib is a selective inhibitor of BCR-ABL/PDGFR/KIT. Flumatinib is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML); Flumatinib effectively overcomes drug resistance of certain KIT mutants. Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 α and VEGF in U266 cell line in a time- and dose-dependent manners.
H9017

KO-539

 		2134675-36-6

KO-539 is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need; In preclinical models, KO-539 inhibits the KMT2A/MLL protein complex and has downstream effects on HOXA9/MEIS1 expression. KO-539 has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML.
H9010

Devimistat

 		95809-78-2

Devimistat (CPI-613) is a lipoic acid analog that inhibits pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts mitochondrial metabolism and shows strong antitumor activity.
H8980

Zandelisib

 		1401436-95-0

Zandelisib (ME-401) is an oral, once-daily, selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ) in clinical development for the treatment of B-cell malignancies.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1